The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a more substantial decrease in body weight and improve metabolic markers, parti